Hematological Malignancies

MLN9708

Description:

MLN9708 is an oral proteasome inhibitor. In this Phase I/Ib study it is administered in patients with relapsed/refractory multiple myeloma and advanced solid tumors who have normal renal function or severe renal impairment.


Study Phase(s): Phase I
Category: Hematological Malignancies
Contact: Epp Goodwin at (210) 450-5798